Notice of Results and Investor Presentation

RNS Number : 3991R

EKF Diagnostics Holdings PLC

01 March 2023

 

EKF Diagnostics Holdings plc

("EKF", the "Company" or the "Group")

Notice of Preliminary Results and Investor Presentation

EKF Diagnostics Holdings plc  (AIM: EKF), the AIM-listed point-of-care business , will announce its preliminary results for the year ended 31 December 2022, on Tuesday 28 March 2023.

Investor Presentation

Julian Baines, Executive Chair, and Marc Davies, Chief Financial Officer, will be hosting a live online presentation relating to the preliminary results via the Investor Meet Company platform at 4.30 pm on Tuesday 28 March 2023. The presentation is open to all existing and potential shareholders.  

Investors can sign up to Investor Meet Company for free and register for the presentation here: https://www.investormeetcompany.com/ekf-diagnostics-holdings-plc/register-investor

Investors who already follow EKF on the Investor Meet Company platform will automatically be invited.

A recording of the presentation, a PDF of the slides used, and responses to the Q&A session will be available on the Investor Meet Company platform afterwards.

EKF Diagnostics Holdings plc		www.ekfdiagnostics.com
Julian Baines, Executive Chair / Marc Davies, CFO		Tel: [phone]
Singer Capital Markets (Nominated Adviser & Joint Broker)			Tel: + 44 ( 0)20 7496 3000
Aubrey Powell / George Tzimas / Oliver Platts
Walbrook PR Limited	Tel: [phone] or [e-mail]
Paul McManus / Lianne Applegarth	Mob: [phone]

About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com )

EKF is a leading   global diagnostics business   with custom manufacturing facilities across sites in the US, UK and Europe for a variety of life science products. EKF is focussed on the following areas:

Point-of-Care	Providing a portfolio of Point-of-Care analysers and consumables, particularly for use in the area of Hematology and Diabetes, for use in hospital and research laboratories, doctor's offices, blood banks and for in-field anaemia screening programmes. EKF has an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analysers in regular use across more than 100 countries.
Central Laboratory	Clinical chemistry, Small lab analysers, Centrifuges Beta-Hydroxybutyrate (β-HB)   LiquiColor , Glycated Albumin, Glycated Serum Protein, Nitro-tab, Procalcitonin
Life Sciences	Enzyme fermentation, Custom products and Bulk fermentation
Contract Manufacturing	Bulk formulation, Sample collection kits, Private labelling, Molecular and forensic kits
Laboratory Testing	Laboratory testing services certified under the Clinical Laboratory Improvement Amendments ("CLIA") for high complexity testing.

 

END

 

 

NORSELFWAEDSEFE